SABS SAB Biotherapeutics Inc

$SABS interesting to note that SAB Biotherapeutics developed human polyclonal antibodies targeting Yersinia pestis, the bacterium responsible for causing both pneumonic and bubonic plague ......

$SABS SAB BIO is developing what could be the first redosable immunotherapy for type 1 diabetes, with registrational data due in 2H 2027 and cash runway through 2028. SAB-142 is a fully human version of rabbit ATG, a mechanism that has preserved insulin-producing beta cells in multiple academic trials. The catch with rabbit ATG is serum sickness, which rules out repeat dosing. In Phase 1, SAB-142 showed no serum sickness and no anti-drug antibodies across 68 participants. Both rabbit ATG and Sanofi’s Tzield are given as a single course. Two registrational studies are underway: SAFEGUARD: Phase 2b, 159 patients with new-onset T1D, enrollment completing in 4Q26 PRISE-hATG: Phase 3 in patients up to two years from diagnosis, co-funded by Breakthrough T1D Behind the pipeline: $208M in cash as of June 30 Runway through 2028 SAFEGUARD fully funded through topline data Next up: first patient in PRISE-hATG in 2H26, SAFEGUARD enrollment complete in 4Q26, and topline data in 2H27.

$SABS 🏥 SAB Biotherapeutics, Inc. announced that the U.S. FDA granted Fast Track designation to SAB-142 for the treatment of new-onset Stage 3 type 1 diabetes. Market-relevant event

$SABS SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

$SABS 🚀 Several bullish catalysts on the horizon! This one deserves more attention, IMO. 🔥 October 10: Two SAB-142 presentations at the Breakthrough T1D Congress, highlighting encouraging Phase 1 data, potential redosing benefits and early signals of insulin-producing beta-cell preservation. 🔥 Q4 2026: Targeted completion of enrollment in the Phase 2b SAFEGUARD trial — a meaningful clinical milestone! 🔥 2027: Anticipated SAFEGUARD topline results, a potentially major value-driving catalyst. 💰 Strong balance sheet: $208M in cash and investments as of June 30, with projected runway through 2028. SAB-142 has the potential to go beyond managing Type 1 diabetes symptoms and actually modify disease progression. With multiple milestones approaching, I’m looking for renewed investor interest and a nice rebound from these levels! 💪📈 Patience could pay off here! 👀

$SABS If you are looking for historical, non-genetically modified use of native bovine antibodies/colostrum for passive immunity in human gut infections, PubMed indexes clinical success tracking back to 1987 for rotavirus, but the 2009 paper is the landmark study for engineering cows to produce targetable human therapeutic antibodies)

$SABS reached measured move price projections of three degrees with bullish divergences on the technical indicators.